Post-Hoc: Rewatch the Boston edition of our China Biotech Debatenews2026-08-12T15:43:32+00:00August 12th, 2026|Endpoints News|
AbCellera, Silence and InduPro all raise significant fundingnews2026-08-12T15:25:55+00:00August 12th, 2026|Endpoints News|
Definium’s LSD drug clears bar in first of two Phase 3 anxiety disorder trialsnews2026-08-12T11:00:54+00:00August 12th, 2026|Endpoints News|
Boulevard Bio dreams big in immunology with $65M, sights on Vera’s IgAN drugnews2026-08-12T10:30:11+00:00August 12th, 2026|Endpoints News|
Did Exelixis use a ‘trivial’ modification to its cash cow to product-hop past a patent cliff? These researchers think sonews2026-08-11T18:29:51+00:00August 11th, 2026|Endpoints News|
AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinoisnews2026-08-11T18:25:36+00:00August 11th, 2026|Endpoints News|
Two health insurers give an AI reality checknews2026-08-11T15:47:19+00:00August 11th, 2026|Endpoints News|
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75Mnews2026-08-11T14:44:13+00:00August 11th, 2026|Endpoints News|
Hims ‘able to move extremely quickly’ if FDA greenlights six wellness peptides, CEO saysnews2026-08-11T13:00:25+00:00August 11th, 2026|Endpoints News|
Epicrispr secures $90M after early data on epigenetic FSHD treatmentnews2026-08-11T12:54:59+00:00August 11th, 2026|Endpoints News|
